# Technical Documentation Reuse Across a Portfolio of Variants

**Niche:** [[niches/medical-device-mfg/device-regulatory-affairs-consulting/profile|Medical Device Regulatory Affairs Consulting]]
**Industry:** [[industries/medical-device-mfg|Medical Device Manufacturing]]
**Type:** Buy & Customize (Vertical Adaptation)
**One-liner:** A product family is dozens of size and configuration variants sharing most of their evidence, and each technical file is assembled as though it were new.
**Tags:** #ocr #large-language-models #graph-ml #workflow-orchestration #compliance

## The Problem
A device portfolio is rarely a set of unrelated products. It is families — sizes, lengths, configurations, and material options sharing a design, a manufacturing process, and most of their supporting evidence. The regulatory documentation for each variant nonetheless has to exist in full: technical file, risk management file, clinical evaluation, biocompatibility rationale, and the traceability from requirements through verification.

Under the European regime this multiplied. Every legacy product required a technical file rebuilt to a new standard on a transition deadline, and certification capacity became the binding constraint for the whole industry — with manufacturers discontinuing products because documenting them was not worth the cost.

The work is done in document templates. Content that is identical across a family is copied, and when a shared element changes — a supplier, a standard revision, a risk assessment — someone has to find every document containing it.

## What Already Exists
Regulatory information management platforms exist and are mature in pharmaceuticals. Document management, structured authoring, and content reuse tooling are commodity technologies used across regulated publishing.

## The Customization Gap
Every available system models a submission as a document set. This work is a network of shared evidence.

**Evidence objects, not document sections.** A biocompatibility rationale, a sterilization validation, or a verification test report is a fact about a design element, referenced by every variant it covers. Modelling it once with its scope of applicability — and generating documents from it — is the structural change, and no pharma-derived platform makes it, because pharma has one product per submission.

**The product family is a graph.** Which variants share which design elements, processes, and materials, so a change propagates automatically to the affected files. Today this is a person's understanding of the portfolio.

**Standards and regulations as monitored dependencies.** When a harmonized standard is revised, every technical file relying on it needs review. That mapping exists in nobody's system, so the response is a manual audit each time.

**Traceability is the deliverable.** Requirement to risk to verification to evidence, demonstrable to an auditor. In documents this is maintained as tables that drift; as a graph it is inherent.

**Multi-jurisdiction, one evidence base.** The same evidence supports submissions in several regimes with different formats and requirements. Format is a rendering problem once the evidence is structured, and a re-authoring problem while it is not.

## Target Customer
Head of regulatory operations at a device manufacturer or the practice leader at a consultancy delivering technical documentation at volume, where documentation cost has become a portfolio-level strategic question.

## Impact If Solved
Documentation burden is now deciding which products stay on the market. Making evidence reusable across a family — rather than re-authored per variant — changes that calculation directly, and turns a standards revision from a manual portfolio audit into a query.
